Phaseline

Targets › ERVCC

ERVCC: drug programs, companies and trials

1 program from 1 company in 2 trials: 2 Phase 2; Infectious disease; next expected readout Nov 2027.

Open in Phaseline: the race on ERVCC, likelihood bands and readouts

Programs

CompanyDrugTargetsHighest phaseConditionsNext expected readout
Altesa BiosciencesVapendavir
VP1 capsid protein inhibitor
ERVCCPhase 2Rhinovirus InfectionNov 2027

Conditions

Rhinovirus Infection (2)

Modalities

small molecule (1)

Companies

Altesa Biosciences (1)

Related targets

–

Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.